Why decisive imaging endpoints need an independent second look
In elite football, video review gives officials an independent, standardized, and traceable way to examine a decisive call. Clinical trial imaging faces a similar problem: the same scan or lesion can be interpreted differently across readers and sites.
When a primary or key secondary endpoint depends on imaging, those differences can affect the credibility of the result. Independent central imaging review (IRC) creates a controlled process for reaching a defensible endpoint assessment.
What IRC contributes
In a multicenter study, scans from CT, MRI, PET-CT, ophthalmic imaging, and other modalities can originate from many devices and acquisition protocols. An IRC model centralizes the data and has trained, qualified readers assess images under a common charter and standardized criteria.
The core controls are:
- independence, so assessment is separated from site-level treatment knowledge and operational pressure;
- blinding, where required by the study design;
- standardization, through a defined charter, acquisition guidance, reader training, and assessment criteria; and
- traceability, with a complete history of receipt, quality control, assignment, reading, adjudication, and change.
Together, these controls reduce avoidable variability and make the imaging endpoint easier to defend in statistical analysis and regulatory review.
When sponsors should consider IRC
Sponsors benefit from involving the imaging team early — ideally while the protocol and endpoint strategy are still being shaped. Early planning can prevent unusable scans, inconsistent acquisition, and late changes to analysis rules.
IRC is especially relevant when:
- a primary or key secondary endpoint is based on imaging;
- the study is single-arm or cannot fully blind investigators;
- the assessment is subjective or known to vary between readers;
- a multicenter design introduces different scanners and acquisition practices;
- imaging could reveal treatment allocation; or
- an accelerated pathway or surrogate endpoint raises the scrutiny placed on imaging evidence.
A connected imaging-review workflow
A reliable platform should carry the study from image receipt to final report without breaking the evidence chain:
- Sites upload images using a controlled process.
- The system checks format, completeness, and acquisition quality and removes direct identifiers according to study rules.
- Images are assigned to qualified readers while maintaining the required blind.
- Readers work in a standardized environment with the protocol's assessment criteria.
- Discordant results follow a predefined adjudication path.
- Project teams monitor progress, queries, turnaround, and data quality without interfering with reader independence.
- Final datasets and reports retain the provenance needed for analysis and inspection.
Technology and expert services belong together
Software alone cannot define a strong imaging endpoint. Sponsors also need an imaging charter, acquisition manual, reader selection and qualification, training, project management, medical support, and ongoing quality analysis.
EClinCloud IRC combines a GxP-aligned imaging-review platform with medical and project services across oncology, ophthalmology, CNS, cardiovascular, and other therapeutic areas. The platform supports DICOM and additional image and document formats, controlled reader workflows, quality management, progress visibility, and standardized outputs.
AI-assisted capabilities can help with tasks such as image quality checks, segmentation, and draft reporting, but endpoint decisions remain governed by the study charter and qualified human review. That balance — automation where it reduces friction, expertise where judgment matters — is what makes a decisive endpoint trustworthy.
